<DOC>
	<DOCNO>NCT02939872</DOCNO>
	<brief_summary>The purpose study evaluate optimal duration antiplatelet therapy Bioresorbable Vascular Scaffold implantation reduce late coronary arterial thrombotic event .</brief_summary>
	<brief_title>Optimal Duration Antiplatelet Therapy After Bioresorbable Vascular Scaffold Implantation Reduce Late Coronary Arterial Thrombotic Events</brief_title>
	<detailed_description />
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Aspirin</mesh_term>
	<mesh_term>Ticlopidine</mesh_term>
	<mesh_term>Clopidogrel</mesh_term>
	<criteria>Age 19 On dual antiplatelet therapy 12months 14months Bioresorbable Vascular Scaffold implantation No history death , serious myocardial infarction , stroke , repeat revascularization , major bleed Contraindication antiplatelet therapy Need continue clopidogrel due stroke , peripheral disease , significant carotid disease recent acute coronary syndrome Major bleed history bleed diathesis Pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>DAPT</keyword>
	<keyword>BVS</keyword>
	<keyword>Bioresorbable Vascular Scaffold</keyword>
	<keyword>Dual Antiplatelet Therapy</keyword>
</DOC>